New european guidelines for management of hypertension: what is relevant for the nephrologist. CommentaryRUILOPE, Luis M.Nephrology, dialysis, transplantation (Print). 2004, Vol 19, Num 3, pp 524-528, issn 0931-0509, 5 p.Article

Long-term protection in at-risk hypertensive patients: A role for Nifedipine GITS?RUILOPE, Luis M.Blood pressure. 2002, Vol 11, Num 2, pp 106-109, issn 0803-7051Article

Barnidipine: A viewpointRUILOPE, Luis M.Drugs (Basel). 2001, Vol 61, Num 7, issn 0012-6667, p. 997Article

Recent developments in the treatment of type 2 diabetes mellitusRUILOPE, Luis M.Cardiovascular drugs and therapy. 2003, Vol 17, Num 2, pp 151-158, issn 0920-3206, 8 p.Article

Valsartan and the kidney: Review of preclinical and clinical dataRUILOPE, Luis M.Advances in therapy. 2001, Vol 18, Num 2, pp 57-66, issn 0741-238XArticle

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidenceRUILOPE, Luis M; SEGURA, Julian.Clinical therapeutics. 2003, Vol 25, Num 12, pp 3044-3064, issn 0149-2918, 21 p.Article

Cardiovascular therapy in patients with renal insufficiencyRUILOPE, Luis M; SEGURA, Julian.Cardiovascular drugs and therapy. 2002, Vol 16, Num 6, pp 497-501, issn 0920-3206, 5 p.Conference Paper

Minor abnormalities of renal function : a situation requiring integrated management of cardiovascular riskSEGURA, Julian; RUILOPE, Luis M.Fundamental & clinical pharmacology. 2005, Vol 19, Num 4, pp 429-437, issn 0767-3981, 9 p.Article

Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION studyRUILOPE, Luis M; SCHAEFER, Angie.Contemporary clinical trials. 2011, Vol 32, Num 5, pp 710-716, issn 1551-7144, 7 p.Article

Treatment of Prehypertension in Diabetes and Metabolic Syndrome: What are the pros?SEGURA, Julian; RUILOPE, Luis M.Diabetes care. 2009, Vol 32, Num 3, pp 5284-5289, issn 0149-5992, 6 p., SUPConference Paper

Are there new threshold and goals in the treatment of arterial hypertension?SEGURA, Julian; RUILOPE, Luis M.European journal of clinical investigation. 2012, Vol 42, Num 8, pp 914-920, issn 0014-2972, 7 p.Article

Blood pressure lowering or selection of antihypertensive agent : which is more important?RUILOPE, Luis M; SEGURA, Julian.Nephrology, dialysis, transplantation (Print). 2006, Vol 21, Num 4, pp 843-845, issn 0931-0509, 3 p.Article

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?ZANCHETTI, Alberto; RUILOPE, Luis M.Journal of hypertension. 2002, Vol 20, Num 11, pp 2099-2110, issn 0263-6352, 12 p.Article

Safety aspects of aldosterone-blocking drugsRUILOPE, Luis M.European heart journal supplements. 2011, Vol 13, Num B, issn 1520-765X, B40-B42Article

The Importance of Integrated Risk Management When Treating Patients with Hypertension : Benefits of Angiotensin II Receptor Antagonist TherapyRUILOPE, Luis M; SEGURA, Julian.Clinical and experimental hypertension (1993). 2008, Vol 30, Num 5, pp 397-414, issn 1064-1963, 18 p.Article

Insulin resistance, hyperinsulinemia, and renal injury : Mechanisms and implicationsSARAFIDIS, Pantelis A; RUILOPE, Luis M.American journal of nephrology. 2006, Vol 26, Num 3, pp 232-244, issn 0250-8095, 13 p.Article

How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?GUSTAFSSON, Finn; SEGURA, Julian; RUILOPE, Luis M et al.Journal of hypertension. 2010, Vol 28, Num 8, pp 1595-1598, issn 0263-6352, 4 p.Article

Renal function and target organ damage in hypertensionRUILOPE, Luis M; BAKRIS, George L.European heart journal. 2011, Vol 32, Num 13, pp 1599-1604, issn 0195-668X, 6 p.Article

What is the optimal pharmacotherapeutic approach to cardiorenal syndrome?RUILOPE, Luis M.Dialogues in cardiovascular medicine. 2011, Vol 16, Num 4, pp 277-283, issn 1272-9949, 7 p.Article

Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive PatientsRUILOPE, Luis M; SCHMIEDER, Roland E.American journal of hypertension. 2008, Vol 21, Num 5, pp 500-508, issn 0895-7061, 9 p.Article

Renal participation in cardiovascular risk in essential hypertensionRUILOPE, Luis M; RODICIO, Jose L.Blood pressure. 2001, Vol 10, Num 5-6, pp 322-326, issn 0803-7051Article

Renal implications of the renin-angiotensin-aldosterone system blockade in heart failureRUILOPE, Luis M; BARRIOS, Vivencio; VOLPE, Massimo et al.Journal of hypertension. 2000, Vol 18, Num 11, pp 1545-1551, issn 0263-6352Article

Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diureticsTAMARGO, Juan; SEGURA, Julian; RUILOPE, Luis M et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 4, pp 527-547, issn 1465-6566, 21 p.Article

Fixed-Dose Combinations as Initial Therapy for Hypertension: A Review of Approved Agents and a Guide to Patient SelectionWAEBER, Bernard; FEIHL, François; RUILOPE, Luis M et al.Drugs (Basel). 2009, Vol 69, Num 13, pp 1761-1776, issn 0012-6667, 16 p.Article

On the importance of estimating renal function for cardiovascular risk assessmentSEGURA, Julian; RUILOPE, Luis M; ZANCHETTI, Alberto et al.Journal of hypertension. 2004, Vol 22, Num 9, pp 1635-1639, issn 0263-6352, 5 p.Article